Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel B Costa

Showing results (1-10 of 175) with videos related to

Pageof 18
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2011
More than just an oncogene translocation and a kinase inhibitor: Kevin's storyDaniel B Costa
Mayo Clinic Proceedings|April 14, 2006
Recurrent infections in multiple myelomaDaniel B Costa
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 15, 2013
Identification of somatic genomic alterations in circulating tumors cells: another step forward in non-small-cell lung cancer?Daniel B Costa
The Lancet. Oncology|March 15, 2016
ALK inhibitors: plateauing systemic and intracranial activity?Daniel B Costa
Cell Cycle (Georgetown, Tex.)|October 21, 2016
Resistance to ALK inhibitors: Pharmacokinetics, mutations or bypass signaling?Daniel B Costa
Translational Lung Cancer Research|March 26, 2015
Clinical development and approval of second generation ALK inhibitors for ALK rearranged lung cancerDaniel B Costa
The Lancet. Oncology|June 13, 2017
Ascending role of next-generation ALK inhibitorsDaniel B Costa
Lung Cancer (Amsterdam, Netherlands)|June 15, 2007
To re-treat or not with gefitinib/erlotinib: This is the question for tyrosine kinase inhibitor-responsive lung cancers that progressDaniel B Costa
Translational Lung Cancer Research|July 15, 2016
Kinase inhibitor-responsive genotypes in EGFR mutated lung adenocarcinomas: moving past common point mutations or indels into uncommon kinase domain duplications and rearrangementsDaniel B Costa
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2008
Response of intracranial metastases to epidermal growth factor receptor tyrosine kinase inhibitors: it may all depend on EGFR mutationsDaniel B Costa, Susumu Kobayashi
Pageof 18

Showing results (1-10 of 175) with videos related to

Sort By:
Pageof 18
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2011
More than just an oncogene translocation and a kinase inhibitor: Kevin's storyDaniel B Costa
Mayo Clinic Proceedings|April 14, 2006
Recurrent infections in multiple myelomaDaniel B Costa
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 15, 2013
Identification of somatic genomic alterations in circulating tumors cells: another step forward in non-small-cell lung cancer?Daniel B Costa
The Lancet. Oncology|March 15, 2016
ALK inhibitors: plateauing systemic and intracranial activity?Daniel B Costa
Cell Cycle (Georgetown, Tex.)|October 21, 2016
Resistance to ALK inhibitors: Pharmacokinetics, mutations or bypass signaling?Daniel B Costa
Translational Lung Cancer Research|March 26, 2015
Clinical development and approval of second generation ALK inhibitors for ALK rearranged lung cancerDaniel B Costa
The Lancet. Oncology|June 13, 2017
Ascending role of next-generation ALK inhibitorsDaniel B Costa
Lung Cancer (Amsterdam, Netherlands)|June 15, 2007
To re-treat or not with gefitinib/erlotinib: This is the question for tyrosine kinase inhibitor-responsive lung cancers that progressDaniel B Costa
Translational Lung Cancer Research|July 15, 2016
Kinase inhibitor-responsive genotypes in EGFR mutated lung adenocarcinomas: moving past common point mutations or indels into uncommon kinase domain duplications and rearrangementsDaniel B Costa
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2008
Response of intracranial metastases to epidermal growth factor receptor tyrosine kinase inhibitors: it may all depend on EGFR mutationsDaniel B Costa, Susumu Kobayashi
Pageof 18